https://jamanetwork.com/journals/jama/fullarticle/2812936#:~:text=Meaning%20In%20participants%20with%20obesity,initial%20weight%20reduction%20is%20unknown.Key PointsQuestion Does once-weekly subcutaneous
-- HARBOR Part 1 trial data in indolent systemic mastocytosis showed elenestinib was well-tolerated with broad symptom improvement, supporting further development to expand and extend company's SM franchise leadership
100% (10/10) overall response rate (ORR) and 70% (7/10) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 6 lines of prior therapy in updated
BMF-219 demonstrated early signs of clinical activity and ability to achieve durable and sustained complete responses (CRs) with minimal residual disease negativity (MRD-neg) in acute myeloid leukemia (AML)
Summary of Clinical Update from Phase 1 Trial of INB-100 • 100% of evaluable treated patients (n=10) remain alive, progression free, and in durable complete remission (CR) as of November 3, 2023,
Pasithea Therapeutics Corp (NASDAQ: KTTA) announced preclinical results from two in vivo studies evaluating the antitumor efficacy of PAS-004 in NRAS mutation
Ascendis Pharma A/S (NASDAQ:ASND) today announced that the U.S. Food & Drug Administration (FDA) has accepted for review the Company's resubmitted New Drug Application (NDA) for TransCon PTH (palopegteriparatide) for
Data showed favorable safety profile, complete response rate and durability in the treatment of patients with relapsed or refractory indolent B-cell Non-Hodgkin Lymphoma100% of patients with follicular